Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
And, sure, it looks promising in animals, but lets look at this one study done in humans, published in 2021 in an obscure journal that focuses on alternative medicine
Weekly Peptides ( Semaglutide , Tirzepatide ): If you miss your weekly injection, take it as soon as you remember, provided it is within 5 days of the missed dose
S2CID 58586667
How does Cagrilintide compare to Pramlintide
May2016;37(5):544-50